Article | March 24, 2021

Jumpstart Cell & Gene Therapy Commercialization With SUT Learning

Source: CPC

By Derek Pendlebury

Jumpstart Cell & Gene Therapy Commercialization With SUT Learning

Recent FDA approvals of the first cell and gene therapies (CGTs) are cause for celebration — but the marathon is not done. Attention has quickly turned to conquering the challenges of commercial-scale manufacturing for these promising therapies. Many of the current CGT manufacturing processes used to supply clinical trials are inadequate for commercial scale. Fortunately, some learning can be adopted from bioprocessing, a process with similar needs.

Understanding The Needs Of CGT Manufacturing

The pipeline of CGTs is impressive. In addition to the recent FDA approved therapies, over 400 therapies1 are in preclinical to Phase 3 development and approximately 1,700 clinical studies are underway globally.


Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.

Subscribe to Bioprocess Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Bioprocess Online